We are live on
!
Find out more
Parallel Advisors Portfolio holdings
AUM
$6.56B
Turnover
11.49%
1-Year Est. Return
32.24%
This Fund
S&P 500
This Quarter
Est. Return
-4.09%
1 Year Est. Return
+32.24%
3 Year Est. Return
+108.68%
5 Year Est. Return
+114.41%
10 Year Est. Return
–
AUM
$2.52B
AUM Growth
-$173M
(-6.4%)
Cap. Flow
-$49.2M
Cap. Flow
% of AUM
-1.95%
Top 10 Holdings %
Top 10 Hldgs %
37.25%
Holding
3,473
New
218
Increased
908
Reduced
1,467
Closed
292
Avg Time Held Equity + Options
3
years
Top 10 Avg Time Held Equity + Options
2.4
years
Top 20 Avg Time Held Equity + Options
2.4
years
Avg Time Held Equity only
3
years
Top 10 Avg Time Held Equity only
2.4
years
Top 20 Avg Time Held Equity only
2.4
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
iShares Fallen Angels USD Bond ETF
FALN
|
+$9.31M |
| 2 |
iShares Core MSCI EAFE ETF
IEFA
|
+$6.87M |
| 3 |
eFFECTOR Therapeutics, Inc. Common Stock
EFTR
|
+$3.6M |
| 4 |
Corcept Therapeutics
CORT
|
+$3M |
| 5 |
State Street SPDR Portfolio Short Term Corporate Bond ETF
SPSB
|
+$2.68M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Vanguard ESG US Stock ETF
ESGV
|
+$9.63M |
| 2 |
iShares Core S&P Total US Stock Market ETF
ITOT
|
+$7.01M |
| 3 |
Microsoft
MSFT
|
+$5.41M |
| 4 |
PIMCO Enhanced Short Maturity Active Exchange-Traded Fund
MINT
|
+$5.16M |
| 5 |
Vanguard FTSE Developed Markets ETF
VEA
|
+$4.44M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 51.1% |
| 2 | Technology | 15.39% |
| 3 | Financials | 8.2% |
| 4 | Healthcare | 7.16% |
| 5 | Consumer Discretionary | 5% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
3001
Cullinan Oncology
CGEM
$901M
| $0 | ﹤0.01% |
+6
| New | +$81 |
2022 Q1
0 quarters
|
|
3002
Cognyte Software
CGNT
$651M
| $0 | ﹤0.01% |
+18
| New | +$208 |
2022 Q1
0 quarters
|
|
3003
Coherus Oncology
CHRS
$165M
| – | – |
-6
| Closed | – | – |
|
3004
Cipher Digital
CIFR
$4.17B
| – | – |
-20
| Closed | – | – |
|
3005
Chimera Investment
CIM
$716M
| $0 | ﹤0.01% |
10
+1
| +11% | +$40 |
2016 Q4
21 quarters
|
|
3006
DELISTED
Civitas Resources
CIVI
| $0 | ﹤0.01% |
2
-43
| -96% | -$2.34K |
2021 Q3
2 quarters
|
|
3007
Clearwater Paper
CLW
$311M
| – | – |
-500
| Closed | -$18K | – |
|
3008
Comtech Telecommunications
CMTL
$43.4M
| $0 | ﹤0.01% |
24
| – | – |
2021 Q1
4 quarters
|
|
3009
Center Bancorp
CNOB
$1.53B
| $0 | ﹤0.01% |
+12
| New | +$401 |
2022 Q1
0 quarters
|
|
3010
PC Connection
CNXN
$2.29B
| $0 | ﹤0.01% |
3
-51
| -94% | -$2.41K |
2020 Q1
8 quarters
|
|
3011
Cohu
COHU
$2.6B
| $0 | ﹤0.01% |
16
+5
| +45% | +$160 |
2021 Q1
4 quarters
|
|
3012
Collegium Pharmaceutical
COLL
$755M
| – | – |
-15
| Closed | – | – |
|
3013
Copa Holdings
CPA
$5.47B
| $0 | ﹤0.01% |
3
-276
| -99% | -$22.7K |
2020 Q2
7 quarters
|
|
3014
Cooper-Standard Automotive
CPS
$382M
| $0 | ﹤0.01% |
30
-46
| -61% | -$752 |
2021 Q3
2 quarters
|
|
3015
Carpenter Technology
CRS
$18.9B
| $0 | ﹤0.01% |
4
-32
| -89% | -$1.12K |
2017 Q1
20 quarters
|
|
3016
Corvus Pharmaceuticals
CRVS
$829M
| $0 | ﹤0.01% |
20
| – | – |
2021 Q2
3 quarters
|
|
3017
Centerspace
CSR
$940M
| – | – |
-17
| Closed | -$2K | – |
|
3018
CTO Realty Growth
CTO
$772M
| $0 | ﹤0.01% |
15
-78
| -84% | -$1.61K |
2021 Q4
1 quarter
|
|
3019
CareTrust REIT
CTRE
$8.65B
| $0 | ﹤0.01% |
+11
| New | +$217 |
2022 Q1
0 quarters
|
|
3020
Citi Trends
CTRN
$416M
| $0 | ﹤0.01% |
9
| – | – |
2021 Q1
4 quarters
|
|
3021
Cytosorbents Corp
CTSO
$9.64M
| – | – |
-11
| Closed | -$1K | – |
|
3022
CuriosityStream
CURI
$161M
| – | – |
-8
| Closed | – | – |
|
3023
Cushman & Wakefield Ltd
CWK
$2.73B
| $0 | ﹤0.01% |
11
-200
| -95% | -$4.24K |
2021 Q4
1 quarter
|
|
3024
Cytokinetics
CYTK
$8.89B
| $0 | ﹤0.01% |
+7
| New | +$249 |
2022 Q1
0 quarters
|
|
|
DADA
3025
DELISTED
Dada Nexus
DADA
| $0 | ﹤0.01% |
25
-10
| -29% | -$97 |
2021 Q4
1 quarter
|
|
Similar funds
Parallel Advisors's Q1 2022 Portfolio in Review
As of Q1 2022, Parallel Advisors held 3,473 positions worth $2.52B, down 6.4% from $2.69B the previous quarter. Its ten largest holdings account for 37% of the portfolio.
Parallel Advisors's Q1 2022 filing shows 218 new, 908 increased, 1,467 reduced and 292 closed positions. Its largest new stake was eFFECTOR Therapeutics, Inc. Common Stock: 27,098 shares worth $2.74M. The largest sale was Vanguard ESG US Stock ETF, an estimated $9.63M.
By sector, the portfolio is most concentrated in Miscellaneous at 51% of assets, down from 51% a quarter earlier, followed by Technology and Financials.
- Parallel Advisors's largest Q1 2022 buy was eFFECTOR Therapeutics, Inc. Common Stock: 27,098 shares worth $2.74M.
- Parallel Advisors added most to iShares Fallen Angels USD Bond ETF in Q1 2022, an estimated $9.31M increase.
- Parallel Advisors's biggest Q1 2022 reduction was Vanguard ESG US Stock ETF, cutting an estimated $9.63M.
- Parallel Advisors fully exited State Street SPDR Nuveen ICE Short Term Municipal Bond ETF in Q1 2022, selling an estimated $1.09M.
- Parallel Advisors's ten largest holdings make up 37% of its $2.52B portfolio in Q1 2022.
- Parallel Advisors opened 218 new positions and closed 292 in Q1 2022.
- Parallel Advisors's portfolio value fell 6.4% quarter-over-quarter to $2.52B.
Based on Parallel Advisors's 13F filing for Q1 2022, filed 28 Apr 2022.